University of Wollongong

Research Online
Faculty of Science, Medicine and Health Papers: part A

Faculty of Science, Medicine and Health

1-1-2012

The treatment of cardiovascular risk in primary care using electronic
decision support (TORPEDO) study: Intervention development and protocol
for a cluster randomised, controlled trial of an electronic decision support
and quality improvement intervention in Australian primary healthcare
David Peiris
The George Institute for Global Health, dpeiris@georgeinstitute.org.au

Tim Usherwood
University of Sydney

Kathryn S. Panaretto
Queensland Aboriginal and Islander Health Council, katiepanaretto@qaihc.com.au

Mark Fort Harris
University of New South Wales, m.f.harris@unsw.edu.au

Jenny Hunt
Aboriginal
and Medical
Research
Council of New South Wales
Follow
thisHealth
and additional
works
at: https://ro.uow.edu.au/smhpapers
Part of the Medicine and Health Sciences Commons, and the Social and Behavioral Sciences
Commons
See next page for additional authors

Recommended Citation
Peiris, David; Usherwood, Tim; Panaretto, Kathryn S.; Harris, Mark Fort; Hunt, Jenny; Patel, Bindu; Zwar,
Nicholas; Redfern, Julie; MacMahon, Stephen; Colagiuri, Stephen; Hayman, Noel; and Patel, Anushka, "The
treatment of cardiovascular risk in primary care using electronic decision support (TORPEDO) study:
Intervention development and protocol for a cluster randomised, controlled trial of an electronic decision
support and quality improvement intervention in Australian primary healthcare" (2012). Faculty of Science,
Medicine and Health - Papers: part A. 4440.
https://ro.uow.edu.au/smhpapers/4440

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

The treatment of cardiovascular risk in primary care using electronic decision
support (TORPEDO) study: Intervention development and protocol for a cluster
randomised, controlled trial of an electronic decision support and quality
improvement intervention in Australian primary healthcare
Abstract
Background: Large gaps exist in the implementation of guideline recommendations for cardiovascular
disease (CVD) risk management. Electronic decision support (EDS) systems are promising interventions
to close these gaps but few have undergone clinical trial evaluation in Australia. We have developed
HealthTracker, a multifaceted EDS and quality improvement intervention to improve the management of
CVD risk. Methods/design: It is hypothesised that the use of HealthTracker over a 12-month period will
result in: (1) an increased proportion of patients receiving guideline-indicated measurements of CVD risk
factors and (2) an increased proportion of patients at high risk will receive guideline-indicated
prescriptions for lowering their CVD risk. Sixty health services (40 general practices and 20 Aboriginal
Community Controlled Health Services (ACCHSs) will be randomised in a 1:1 allocation to receive either
the intervention package or continue with usual care, stratified by service type, size and participation in
existing quality improvement initiatives. The intervention consists of point-of-care decision support; a risk
communication interface; a clinical audit tool to assess performance on CVD-related indicators; a quality
improvement component comprising peer-ranked data feedback and support to develop strategies to
improve performance. The control arm will continue with usual care without access to these intervention
components. Quantitative data will be derived from cross-sectional samples at baseline and end of study
via automated data extraction. Detailed process and economic evaluations will also be conducted. Ethics
and dissemination: The general practice component of the study is approved by the University of Sydney
Human Research Ethics Committee (HREC) and the ACCHS component is approved by the Aboriginal
Health and Medical Research Council HREC. Formal agreements with each of the participating sites have
been signed. In addition to the usual scientific forums, results will be disseminated via newsletters, study
websites, face-to-face feedback forums and workshops. Trial registration: The trial is registered with the
Australian Clinical Trials Registry ACTRN 12611000478910.
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ABSTRACT
Background: Large gaps exist in the implementation
of guideline recommendations for cardiovascular
disease (CVD) risk management. Electronic decision
support (EDS) systems are promising interventions to
close these gaps but few have undergone clinical trial
evaluation in Australia. We have developed
HealthTracker, a multifaceted EDS and quality
improvement intervention to improve the management
of CVD risk.
Methods/design: It is hypothesised that the use of
HealthTracker over a 12-month period will result in:
(1) an increased proportion of patients receiving
guideline-indicated measurements of CVD risk factors
and (2) an increased proportion of patients at high risk
will receive guideline-indicated prescriptions for
lowering their CVD risk. Sixty health services
(40 general practices and 20 Aboriginal Community
Controlled Health Services (ACCHSs) will be
randomised in a 1:1 allocation to receive either the
intervention package or continue with usual care,
stratified by service type, size and participation in
existing quality improvement initiatives. The
intervention consists of point-of-care decision
support; a risk communication interface; a clinical
audit tool to assess performance on CVD-related
indicators; a quality improvement component
comprising peer-ranked data feedback and support to
develop strategies to improve performance. The control
arm will continue with usual care without access to
these intervention components. Quantitative data will
be derived from cross-sectional samples at baseline
and end of study via automated data extraction.
Detailed process and economic evaluations will also
be conducted.

ARTICLE SUMMARY
Article focus
▸ The development of a multifaceted decision
support tool and quality improvement (QI)
intervention.
▸ The methods to test the effectiveness of this intervention in improving guideline-recommended
screening for cardiovascular risk and management
for individuals identified at high risk.

Key messages
▸ This study tests a novel intervention that incorporates point of care decision support, risk
communication and resources for patients,
health service audit tools and use of data for
supporting QI initiatives.
▸ In addition to assessing practitioner performance on indicators correlated with improved
health outcomes, the study also includes
detailed process and economic evaluations.

Strengths and limitations of this study
▸ The strengths of the study are that it assesses an
innovative complex intervention that is implemented in routine primary healthcare settings. It will
provide rigorous evidence on process, clinical and
economic outcomes and addresses an important
issue facing health systems worldwide—namely
scalable interventions that are able to achieve
improvements in performance.
▸ The main limitation is that it is conducted in one
country, Australia, and thus its generalisability
may be influenced by the prevailing health
system context.
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Ethics and dissemination: The general practice component of the
study is approved by the University of Sydney Human Research
Ethics Committee (HREC) and the ACCHS component is approved by
the Aboriginal Health and Medical Research Council HREC. Formal
agreements with each of the participating sites have been signed.
In addition to the usual scientific forums, results will be
disseminated via newsletters, study websites, face-to-face feedback
forums and workshops.
Trial registration: The trial is registered with the Australian Clinical
Trials Registry ACTRN 12611000478910.

BACKGROUND
Cardiovascular disease burden in Australia
Despite recent gains, cardiovascular disease (CVD)
remains Australia’s biggest killer accounting for 18%
of the total disease burden and 11% of health system
expenditure in Australia.1 Aboriginal and Torres Strait
Islander peoples experience around ﬁve times greater
CVD burden than other Australians.2 Current estimates
project that by 2030 annual CVD expenditure will rise by
around 100% to $16 billion.3 Primary care-based strategies that improve the uptake of best-practice recommendations could substantially reduce both the
Indigenous and non-indigenous CVD burden and help
improve health system efﬁciencies.
Evidence-practice gaps in CVD prevention
In addition to lifestyle modiﬁcation, a number of drug
therapies have been shown to be highly effective in preventing cardiovascular events, primarily through modiﬁcation of blood pressure, lipids and platelet function.4–8
However, there is compelling evidence of the failure of
current clinical practice to adequately implement such
treatments, and to translate current knowledge into
maximally improved health outcomes. Three recently
completed cross-sectional studies of CVD risk management in Australian general practice and Aboriginal
Community Controlled Health Service (ACCHS) settings9–11 demonstrated that 50% of routinely attending
adults lacked sufﬁcient recorded information to comprehensively evaluate vascular risk. For those identiﬁed at
high vascular risk, only around 40% were prescribed
guideline-indicated medicines. Similar ﬁndings have
been noted in other Australian studies.12–15 These
surveys have demonstrated failure to adequately implement the ‘absolue risk’ paradigm for CVD prevention.
Numerous tools are now available to estimate an individual’s 5-year or 10-year absolute risk of coronary heart
disease and/or CVD.16–21 Despite their availability, only
a minority of Australian general practitioners (GPs) use
these risk assessment tools, and then primarily for
patient education, rather than to guide management
decisions.9 22 23 Australia’s ﬁrst absolute risk assessment
guideline was released in 2009 by the National Vascular
Disease Prevention Alliance (NVDPA)17 and in 2012 this
was augmented by a single management guideline.24
2

Despite these guidelines now becoming available, there
remain substantial challenges in effectively implementing their recommendations. We have found that
CVD-risk assessment and treatment work best when
negotiated as part of a shared decision-making
approach, taking an average of 15 min even where only
one guideline needs to be consulted.25
The role of electronic decision support in closing evidence
practice gaps
Electronic decision support (EDS) systems are among
the most promising interventions to improve uptake of
guideline-based recommendations in clinical practice. In
ﬁve systematic reviews on the effectiveness of EDS,
around two-thirds of studies demonstrated improvement
in practitioner performance.26–30 One systematic review
identiﬁed four decision support system features associated with improved performance: incorporation in
routine work ﬂow, provision at the time and location of
patient consultation, use of computer-based tools and
provision of treatment recommendations rather than
just assessments.28 Of 32 systems that incorporated all of
these elements, signiﬁcant improvements in performance were noted in 30. There are relatively few controlled evaluations of EDS systems that are integrated
with electronic health records (EHRs) in the area of
CVD.31–35 Effect sizes vary greatly depending on the variables studied and the type of EDS system. In one systematic review of on-screen point-of-care reminder systems
the absolute improvements ranged from 1% to 24% for
test ordering and from 3% to 28% for medication prescribing.27 In New Zealand, an EDS system that is fully
integrated with the country’s most popular primary care
software has been successfully implemented.36 To date,
we are unaware of an EDS system aimed at assisting comprehensive cardiovascular risk management based on
Australian guidelines. Furthermore, we are not aware of
any randomised evaluations of such systems in Australian
primary care settings. Globally, few examples exist and
the evidence base remains poor.
INTERVENTION DEVELOPMENT
HealthTracker is a novel EDS system to facilitate
guideline-based assessment and management of CVD
risk. Outlined below are the key steps taken in the development of the intervention.
Algorithm development and validation
A single screening and management algorithm was
developed based on a synthesis of recommendations
from several primary care screening and management
guidelines (table 1). The algorithm calculates a person’s
5-year absolute CVD risk based on the Framingham risk
equation and NVDPA recommendations 17 20 and provides management recommendations based on the
guidelines listed in table 1. In 2008–2009, a β-version of
HealthTracker was developed in a stand-alone software
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Table 1 Guidelines used in the HealthTracker algorithm
Professional organisation

Guideline

National Vascular Disease Prevention Alliance

Guidelines for the Assessment of Absolute Cardiovascular Disease Risk
2009
Reducing Risk in Heart Disease 2008
Guide to Management of Hypertension 2008- Updated Aug 2009
Aspirin for cardiovascular disease prevention 2003
The Lipid Position Statement 2005

National Heart Foundation

National Heart Foundation/ Cardiac Society of
Australia and New Zealand
National Stroke Foundation
Royal Australian College of General
Practitioners
Diabetes Australia

Kidney Health Australia
Department of Health and Aging

Clinical Guidelines for Stroke Management 2010
Guidelines for preventive activities in general practice 2009
Diabetes Management in General Practice 2010/2011
NHMRC Evidence Based Guidelines for Type 2 Diabetes 2009- Case
Detection and Diagnosis
NHMRC Evidence Based Guidelines for Type 2 Diabetes 2009- Diagnosis,
Prevention and Management of Chronic Kidney Disease
Chronic Kidney Disease Management (CKD) in General Practice 2007
Schedule of Pharmaceutical Benefits Scheme 2011 General Statement for
Lipid Lowering Drugs

system and independently validated for accuracy and
compliance with the prevailing guidelines.22 In 2011,
the algorithm was extensively revised to incorporate
recommendations from newly published guidelines.
A similar validation process was then conducted consisting of three levels:
▸ Level 1 was an iterative process where each of the calculations programmed in the algorithm were tested
to ensure they were consistent with recommendations
from the guidelines. This was conducted using deidentiﬁed data from 337 patients involved in the pilot.
Programming modiﬁcations were made where necessary and all variables were retested to ensure they
were programmed correctly.
▸ Level 2 involved giving a plain language summary of
the algorithm to a research fellow who had not been
involved in the development of the algorithm. She
independently programmed the algorithm into a statistical software package. Using data from 9077 patients
from three representative cross-sectional general practice surveys,9–11 we then assessed whether the outputs
from HealthTracker correlated with those generated
from the independently programmed version. For 60
of the 63 output variables HealthTracker achieved
perfect correlation with the independently programmed version. For the remaining three variables
minor programming errors were identiﬁed and
corrected.
▸ Level 3 involved user acceptance testing and scrutiny
of the algorithm by the study investigators, 20 health
professionals working in both General Practice
and ACCHSs and three national professional
organisations—the NVDPA, the Royal Australian
College of General Practitioners and the National
Prescribing Service. Following this feedback, a
number of minor algorithm and user interface

changes were incorporated into the ﬁnal version of
the tool. The level 2 testing process was repeated
following these changes and perfect correlation
between HealthTracker and the independently programmed version was achieved for all variables.

Integration of HealthTracker with the primary care
electronic health record and quality improvement tools
HealthTracker interfaces with the two Australian clinical
practice software systems most commonly used in general
practice and ACCHS settings (Medical Director and Best
Practice). There are four components to the system:
▸ Point-of-care decision support: HealthTracker is built in
the Pen Computer Systems PrimaryCareSidebar,
third-party software that interacts with the primary
EHR system. Figure 1 shows the HealthTracker user
interface
and
its
integration
with
the
PrimaryCareSidebar and the EHR. A prompt function
is used to encourage health professionals to conduct
a cardiovascular assessment if guideline recommended. Where possible, the tool populates with
information from the patient’s record. If essential
information required for the calculation of absolute
risk is missing or out-of-date, a trafﬁc light prompt
alerts the health professional and updated information can be entered. If the patient is receiving suboptimal treatment then a trafﬁc light recommendation is
made to consider initiation of treatment or additional
agents. Information about eligibility for the Australian
Government Pharmaceutical Beneﬁts Scheme subsidy
is provided if lipid lowering medicines are recommended. All outputs are qualiﬁed by statements
emphasising that the ﬁnal decision to commence or
change therapy should be made by the health professional based on all available information.
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Figure 1 HealthTracker_user interface.

▸ A patient-oriented risk communication interface: A key
ﬁnding from the pilot evaluation was the role of the
output in risk communication. GPs wanted to interactively alter current risk factors and perform ‘what
if’ scenarios to demonstrate to patients the effects of
current and altered risk over time. This functionality
has been built into HealthTracker and uses the
concept of ‘Heart Age’ to demonstrate to patients the
discrepancy between current risk and an ideal risk
based on well-controlled risk factor levels. Figure 2
shows an example of how a patient’s heart age
changes with the effect of smoking cessation.
▸ A data extraction tool: This provides health professionals
with immediate feedback on their performance on
screening and management of CVD risk for their
entire patient population. Figure 3 shows an example
of screening performance for a range of CVD risk
factors. Practitioners can use this tool to identify
speciﬁc patients in whom there may be a particular
risk factor measurement missing or a potential prescribing gap. Customised point-of-care prompts can
then be created. When a patient record is opened an
alert is provided to notify the practitioner of the particular management issue and this can then be
actioned.
▸ A quality improvement (QI) component: This is aligned
with the methods of the Improvement Foundation of
Australia
(IFA)
Australian
Primary
Care
Collaboratives (APCC) programme. Deidentiﬁed data
4

extracts of clinical performance are securely exported
to a web-based central repository managed by the
IFA. This repository provides access to site-speciﬁc
feedback reports on performance compared with
other anonymised sites. Figure 4 shows an example of
how this information is presented.

STUDY OBJECTIVES
The TORPEDO study will test HealthTracker’s performance in assisting health professionals and patients in
making evidence-based management decisions to help
prevent heart attack, stroke and related conditions.
Hypotheses
Using a cluster randomised, controlled trial design, two
speciﬁc hypotheses will be tested. Compared with
control practices, those practices randomised to receive
HealthTracker will have:
1. An increased proportion of patients receiving appropriate (guideline-indicated) measurements of their
CVD risk factors.
2. An increased proportion of patients at high risk
receiving appropriate (guideline-indicated) prescriptions for the management of their CVD risk.
These aims will be augmented by formal economic
and process evaluations to provide crucial information
on large-scale implementation and sustainability.
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Figure 2 HealthTracker—cardiovascular disease-risk communication interface.

STUDY DESIGN
HealthTracker will be evaluated using a cluster
randomised, controlled trial design. At end of study,
HealthTracker will be made available to both the intervention and control arms for a further 12 months free of
any licence fees. The study schema including site and
patient eligibility criteria are highlighted in ﬁgure 5.
Eligibility criteria
Health service
1. Use of Medical Director or Best Practice for EHR
management.
2. Exclusive use of these systems to record risk factor
information, pathology test results and prescribe
medications.
3. Agreement by all GPs and other designated staff to
use HealthTracker.
Services that do not have a compliant software system
will be excluded from participation. Services using
‘hybrid’ paper and electronic systems for recording risk
factor information, pathology results and medication
prescription will also not be eligible to participate.
Patients
1. Aboriginal and Torres Strait Islander people 35+
years and all others 45+ years (age criteria are based
on NVDPA guideline screening recommendations37).

2. Attendance at the general practice or ACCHS at least
three times in the previous 24-month period AND at
least once in the previous 6-month period.
Site recruitment
Participating general practices have been recruited
from the Sydney region in collaboration with primary
healthcare organisations known in Australia as Medicare
Locals. Participating ACCHSs have been recruited in
partnership with two state representative bodies for
ACCHSs, the Aboriginal Health & Medical Research
Council (AH&MRC) of NSW and the Queensland and
Aboriginal Islander Health Council (QAIHC).
A $500AUD reimbursement to participating sites will be
made to partially compensate for health service staff
time commitment to study-related activities. Sites randomised to the intervention will receive training support in
use of the system predominantly via face-to-face visits
and webinars. All licence costs and technical support
associated with the intervention will be provided free to
the intervention sites in the ﬁrst 12 months and to all
sites for the following 12 months after completion of
the trial. A newsletter and networking web site will be
provided to participating sites. Royal Australian College
of General Practitioners Quality Assurance and
Continuing Professional Development points will be
offered to participating GPs in both arms of the trial.

Peiris D, Usherwood T, Panaretto K, et al. BMJ Open 2012;2:e002177. doi:10.1136/bmjopen-2012-002177
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Figure 3 Sample output of performance in cardiovascular disease-risk factor screening.

Randomisation
Sixty services (40 general practices and 20 ACCHSs) will
be randomised in a 1:1 allocation to use HealthTracker
or ‘usual care’ for 12 months. Clusters will be stratiﬁed
at three levels:
1. ACCHS versus general practices.
2. Service size (<500 patients meeting eligibility criteria
vs >=500).
3. Participation in existing QI programmes (current
involvement in one of ﬁve national and state programmes involving regular audit and feedback versus
past or never involved in these programmes).
A site assessment survey will be administered to all
sites to assess for service eligibility and these stratifying
variables. Permuted block randomisation will be centrally performed using a web-based form. As this is a
pragmatic trial, allocation will be single blinded with
outcome analyses conducted blinded to treatment
allocation.
Intervention group
The intervention arm will receive the four components
of the system described above ( point-of-care decision
support software, risk communication tools, data extraction tools and access to the QI portal). Clinical staff will
be given training in use of the tools and a support
service will be available for any technical queries. One
initial face-to-face training visit and subsequent site visits
and webinars targeting strategies to improve quality of
care will be provided. Unless requested by health services the intervention will not be modiﬁed or
6

discontinued. Reasons for discontinuation will be outlined and all analyses will be conducted on an
intention-to-treat basis (see below).
Control group
Sites allocated to this arm will continue usual practice
with their current systems without the implementation
of HealthTracker. As the George Institute holds exclusive
rights to the distribution of the system, there is no possibility of control sites having access to HealthTracker. If
these sites already routinely use data extraction tools for
assessing their quality of care then this will continue as
normal. As with the intervention arm, services participating in any QI initiatives will continue participation as
usual. For those sites not routinely using data extraction
tools, the automated data extraction tool will be temporarily installed for data collection purposes only and then
uninstalled that same day. A feedback report on performance will be provided at study completion only.
Quantitative data collection
Cross-sectional data will be collected in an automated
manner for all patients who satisfy the eligibility criteria
at each service (ﬁgure 5). These data will then be sent
securely to the George Institute via an export function
for the analysis of primary and secondary outcomes.
Prerandomisation: 1 month prior to randomisation, deidentiﬁed data will be collected from all sites. These data
will be fed back to all sites as a formal report highlighting areas where data quality issues may occur.
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Figure 4 Sample display from the quality improvement portal.

Randomisation: Baseline data will be collected and sites
will be randomised to intervention or control.
End of intervention period: At the end of 12 months,
data will be collected in both study arms.

Primary outcomes
▸ Change in the proportion of eligible patients receiving appropriate measurements of their CVD risk in
the previous 12 months (measured at randomisation
and at 12 months).
▸ Change in the proportion of eligible patients assessed
at high CVD risk receiving appropriate prescriptions
for their CVD risk factors in the previous 12 months
(measured at randomisation and 12 months).
Appropriate measurement of CVD risk factors is
deﬁned as having recorded or updated all the essential
risk factors for the measurement of CVD risk (smoking
status, blood pressure (BP) in the previous 12 months,
total cholesterol and high-density lipoprotein (HDL)
cholesterol in the previous 24 months) among those in
whom risk assessment is guideline indicated. Unless

explicitly recorded, diagnoses of diabetes or left ventricular hypertrophy will be assumed to be absent.
High CVD risk is deﬁned as a calculated 5-year CVD
risk of >15%, a history of CVD or the presence of any
clinically high-risk conditions (as per NVDPA recommendations). Based on audit data, this is expected to
comprise ∼30% of the patient population.10 11
Appropriate prescriptions is deﬁned as a prescription
for one or more BP lowering drugs and a statin for
people at high risk without CVD; or a prescription for
one or more BP lowering drugs and a statin and an antiplatelet agent (unless contraindicated by oral anticoagulant use) for people with established CVD.

Secondary outcomes
▸ Change in the measurement of individual risk factors
separately (smoking status, BP, cholesterol, other
non-Framingham risk factors—BMI, chronic kidney
disease (CKD) screening with urinary Albumin
to Creatinine ratio, estimated Glomerular Filtration
Rate);
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prescription of appropriate medicines to high-risk
patients (second primary outcome) is 50%. This is
based on our published data on drug prescriptions
for individuals with and without established CVD.9–11
4. An intraclass correlation coefﬁcient of 0.05 for both
primary outcomes based on our audit data.9–11
5. Two-sided α=0.05
Data analysis will be performed on an intention-totreat basis using generalised estimating equations.38
Subgroup analyses will be carried out using the three
prespeciﬁed strata: (1) ACCHS versus general practices,
(2) service size (small vs large) and (3) current participation in QI programmes vs past or no involvement in
these programmes.

Figure 5 TORPEDO study schema.

▸ Intensiﬁcation of existing medication regimes among
patients at high CVD risk (additional BP and
lipid-lowering agents);
▸ Changes in mean systolic BP, total cholesterol, LDL
cholesterol and HDL cholesterol;
▸ New CVD and CKD diagnoses.
Statistical considerations
Randomisation of 60 services (30 per arm) will provide
90% power to detect a ≥10% absolute higher occurrence in each primary study outcome among practices
receiving HealthTracker. The following assumptions are
based on our three audits in ACCHSs and mainstream
general practices9–11 and include an assumed improvement of 10% in the two primary outcomes in control
practices as a result of study participation.
1. Cluster size of eligible population will range from 200
in a small service through to 2000 in a large service.
An average cluster size of 750 is assumed.
2. Recording rates of essential risk factors needed for
risk assessment in the target group (ﬁrst primary
outcome) average 50%.10 11
3. Thirty per cent of the cluster will be either be at high
CVD risk or have established CVD (n=250) and
8

Economic evaluation
The economic evaluation will have a trial-based component and a modelled evaluation of long-term costs and
outcomes. The incremental cost will be based on software, training and other costs incurred with transitioning practices to using HealthTracker. This will help
determine the cost barriers experienced by different
practices in adopting the system. Data on medications,
laboratory tests, consultations and newly recorded diagnoses of CVD events incurred by eligible patients during
the trial will be obtained from the data extraction tools.
Costs will be calculated from prevailing Medicare rates
and standard Australian National Diagnosis Related
Groups cost weights for CVD hospitalisations. The incremental cost consequences of the HealthTracker system
in achieving each of the primary outcomes will then be
estimated, for example, cost per eligible patients
assessed at high CVD risk receiving appropriate prescriptions. Trial-based data, however, cannot capture costs
and outcomes beyond the trial. To address this, a modelled economic evaluation will enable quality of life and
survival to be examined and allow incremental costeffectiveness ratios to be calculated in terms of cost per
Quality Adjusted Life Years gained. Using a Markov
model, the eligible patient population in both study
arms will be hypothetically tracked over an extended
period. Transition between various deﬁned health states,
costs and quality of life attached to various health states
and the projected long-term intervention effects from
that observed in the trial will be based on published evidence. With appropriate discounting, estimates of longterm costs and outcomes will fold out of the model.
Sensitivity analyses will be conducted on discount rate,
uncertainty in outcome estimates and assumptions made
in costing (eg, varying efﬁciencies with different patient
practice ratios to those of the trial setting). This will
better inform policy makers as to the resource consequences of rolling out this programme to scale.
Process evaluation
The qualitative evaluation of the β-version of
HealthTracker suggested that a critical factor affecting
the uptake of EDS interventions is whether and how
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they become embedded in routine healthcare.22 In the
TORPEDO trial we will build on this observation
through a detailed process evaluation to better appreciate the factors that might inﬂuence sustainability beyond
the trial setting. Two qualitative methods will be used to
explore these factors.
Semistructured interviews with health professionals and staff
A maximum variation sample will be taken to ensure
diverse opinions are gained from patients, clinical and
managerial health staff and sites with low and high
uptake of the intervention.39 Key issues to be explored
will include (1) how practitioners use HealthTracker;
(2) what effects it has on organisational practices and
personnel and (3) what are patients’ experiences of
being presented with HealthTracker outputs and what
impact does this have on the healthcare encounter.
Individual informed consent will be sought and data will
be collected towards the end of the intervention period
so as not to unduly inﬂuence trial outcomes.
Audio/video ethnography
A key component of understanding barriers/enablers to
use of HealthTracker is a better appreciation of how
practitioners and patients use it at the point of care.
Data collection using audio/video recording will capture
how technological innovations are actually used in practice.40 Ethnographic analysis will greatly augment the
interview accounts and will particularly shed important
light on (1) how the intervention impacts on the ﬂow of
the clinical encounter; (2) how risk information is communicated between health professional and patient and
(3) how the patient receives and interprets the information and the role it may play in shared decision-making
processes. Although audio/video recorded clinical
encounters are commonly used for primary care teaching purposes, such a technique can be potentially sensitive and therefore will be restricted to a small number of
sites. Recordings will be conducted toward the end of
the intervention period when both health staff and
patients are thoroughly familiar with the system. This
will occur over a 1-week period at each site. Participants
who are approached for an interview will be invited to
participate in this component. They will be given the
option of having their healthcare encounter audio or
video recorded. A follow-up interview will be arranged
with these participants (both staff and patients) where
the recording is played back for participant interpretation of the data.
These data will be supplemented by project ofﬁcer
ﬁeld notes to identify any key processes, events, stafﬁng
and other resource issues occurring during the
intervention period that may be relevant in gaining a
better understanding of barriers and facilitators to
implementation.
A multidisciplinary research team will guide the analysis process. As is common with qualitative inquiry, data
analysis will commence early and be conducted

contemporaneously with data collection. This method
allows for interview content to be reﬁned for subsequent
data collection and to actively pursue emergent themes
of interest. Although interviewing will continue until
thematic saturation is achieved and therefore the exact
number of interviews is unknown, we anticipate from
prior experience that around 80 interviews (40 patients
and 40 staff ) will provide sufﬁciently rich data to meet
our objectives.
Interview data will be digitally recorded, and professionally transcribed. NVivo 9 (QSR International
Melbourne, Victoria, Australia) will be used to assist with
data organisation and coding for key themes. Video data
will be directly analysed and coded for key themes
within NVivo. Feedback of ﬁndings to participants will
be provided by a variety of methods, including workshops, summary reports, newsletters and via the study
website.

ETHICAL CONSIDERATIONS
The general practice component of the study is
approved by the University of Sydney Human Research
Ethics Committee (HREC) and the ACCHS component
is approved by the Aboriginal Health and Medical
Research Council HREC. Formal agreements with each
of the participating sites have also been signed.
Quantitative data will be obtained from deidentiﬁed clinical audits. Ethical approval to grant waiver of the usual
requirement to obtain individual patient consent has
been obtained. In participating ACCHS sites, eligible
patients can request to ‘opt out’ from having data in the
clinical audit data extracts exported. Data exports will be
compliant with privacy legislation, centrally managed by
the George Institute and held in strict conﬁdence. Some
individual health professionals (GPs, practice nurses,
etc) and patient participants will have their informed
consent taken at the site to allow data collection
through semistructured in-depth interviews and/or
the use of audio/videotaped healthcare encounters.
Participation in this component will be optional. Patient
information statements and consent forms have been
approved by each ethics committee and formatted in
accordance with their own guidelines and requirements.
The study will be conducted in accordance with the
principles set out in the National Health and Medical
Research Council and the NSW Aboriginal Health and
Medical Research Council guidelines. Speciﬁc effort will
be taken to respect the autonomy and governance of
participating ACCHSs. The intellectual property rights
of ACCHSs will be recognised and preserved. It is also
recognised that ACCHSs have rights and responsibilities
regarding the use of health-related information for their
attending clients. Collaborators on the TORPEDO study
will be encouraged to disseminate information from the
project in a manner that supports health improvement
for Aboriginal and Torres Strait Islander peoples and
local beneﬁt to participating ACCHSs.
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DISCUSSION
The TORPEDO study will seek to provide reliable evidence about the effectiveness of QI interventions
incorporating EDS in Australian primary care settings.
The implications of use of such systems for CVD risk
management extend well beyond being a point-of-care
clinical resource. Improving health system performance
is central to the aims of this initiative and this is especially pertinent to addressing Aboriginal health inequities where the CVD burden is ﬁve-fold greater. There is
potential for substantially better health outcomes
from CVD in Australia with improved implementation of
existing evidence in primary healthcare, where most of
the opportunity to manage cardiovascular risk occurs.
The strategy proposed is the ﬁrst of its kind in Australia
and is strongly aligned with national strategy recommendations for health system reform. If effective,
HealthTracker could have widespread applicability
for the prevention and management of other chronic
diseases.
Strengths and limitations of this study
The strengths of the study are that it assesses an innovative complex intervention that is implemented in
routine primary healthcare settings. It will provide rigorous evidence on process, clinical and economic outcomes and addresses an important issue facing health
systems worldwide—namely scalable interventions that
are able to achieve improvements in performance.
The main limitation is that it is conducted in one
country, Australia, and thus its generalisability may be
inﬂuenced by the prevailing health system context.
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